MENU
NKTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Nkarta (NKTX) Ownership - Who owns Nkarta?
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies... Show more
Profile
Industry
N/A
Address
1150 Veterans Boulevard
Phone
+1 905 407-1049
Employees
150
Web
https://www.nkartatx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
146.88M
P/E Ratio
N/A
Total Cash
265.51M
Projected Growth
N/A
Total Debt
78.91M
Revenue
N/A
Risk (Beta)
1.32
Dividend Yield
N/A
Total Cash/Share
3.74
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
NKTX
Capitalization
147M
P/E Ratio
N/A
Risk (Beta)
1.32
Dividend Yield
N/A
Total Cash
266M
Total Cash/Share
3.74
Total Debt
78.9M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
379M
P/B Ratio
0.40
Cash Flow
N/A
Earnings
-1.45
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
14.48
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-122.8M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-21.24
Shares Held By Institutions
136M
Shares Outstanding - Current
71M
Total Liabilities
91.8M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-14.859
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
1150 Veterans Boulevard
Phone
+1 905 407-1049
Employees
150
Web
https://www.nkartatx.com